The Magnify incubator at the California NanoSystems Institute at UCLA is celebrating the growth of one of its companies. Partillion Bioscience is a venture-backed life science company commercializing Nanovials, a next generation single-cell analysis platform.
Partillion was co-founded by CNSI member Dino Di Carlo, the Armond and Elena Hairapetian Professor of Engineering and Medicine at the UCLA Samueli School of Engineering, and Joe de Rutte, UCLA alumni and current CEO of Partillion.
Originating from Di Carlo’s lab at UCLA, the technology propelling Partillion’s products has garnered attention and accolades, securing the 2020 Society for Laboratory Automation and Screening (SLAS) Innovation Award and 2022 SLAS New Product Award and featuring in renowned journals such as Nature Communications, Science Advances, and ACS Nano.
The company has been based in CNSI’s on-campus startup incubator, Magnify, since December 2020.
Partillion’s award-winning nanovial technology enables customers to accelerate therapeutic development to address the most difficult diseases and provide advanced scientific insights.
Partillion recently announced the closing of a $5 million financing round led by ND Capital and a multiyear partnership with Alloy Therapeutics for therapeutic discovery services.
This financing will fund growth and expansion of new functional single-cell analysis and sorting product lines for drug discovery, enabled by Partillion’s proprietary Nanovial technology.
“This opportunity is pivotal for Partillion, allowing us to continue developing innovative single-cell solutions and extending our groundbreaking technology to more users at an accelerated rate, said de Rutte. “Magnify has played a crucial role in our journey, enabling us to grow at our own pace while providing access to the vibrant UCLA ecosystem, including facilities, talent, and collaborators. We are excited about making this cutting-edge technology increasingly accessible to researchers, fostering advancements in the burgeoning biotech ecosystem of Southern California and beyond.”
The announcement comes as Partillion is graduating from their footprint at the Magnify incubator at CNSI and moving to new office space in Pasadena.
“Partillion’s continued footprint in LA keeps us connected to the burgeoning biotech ecosystem here and enables us to support our local customers developing novel biologics and cell therapies,” said Di Carlo.
“Magnify has been proud to be a partner in supporting Partillion’s remarkable growth and success, said Nikki Lin, Director of Entrepreneurship and Commercialization at CNSI. “Under Joe’s leadership, a UCLA start-up has grown rapidly into a thriving enterprise that will continue to have a deepening impact on advancements in healthcare as well as the greater Los Angeles region.”